Type 1 Diabetes Articles & Analysis
134 news found
This peptide-based API acts as an agonist of the glucagon-like peptide-1 (GLP-1) receptor. By enhancing insulin production, Semaglutide enables exploration into methods of regulating blood sugar levels, making it a focal point for researchers investigating metabolic regulation. ...
We’re starting the week by welcoming Rebecca Warfvinge and João Vieira to the BPC team! Both join us as Technical Sales Scientists, bringing research expertise that will help our customers advance their work. Rebecca holds a master’s degree in biomedicine and has since conducted research for several years at Lund University in leukemia, where she used single-cell methods to ...
Ace Therapeutics launches its cutting-edge in vivo models of diabetes mellitus. These models—chemically induced, genetically engineered, or diet-induced—have the potential to advance diabetes research by giving scientists the means to support the identification and development of novel treatment approaches. ...
Ace Therapeutics, a leading provider of preclinical research services and products, is proud to announce the launch of its extensive suite of diabetic mouse models. These models have been specifically designed to enable research on different types of diabetes including type 1, type 2, and ...
This novel glucagon-like peptide-1 (GLP-1) receptor agonist has generated significant excitement within the pharmaceutical and life sciences industries due to its remarkable efficacy in managing type 2 diabetes. ...
.: 1143516-05-5), SNAC (CAS NO.: 203787-91-1), tBuO-Ste-Glu(AEEA-AEEA)-OtBu (CAS NO.:1118767-16-0), and Fmoc-L-Lys[Oct-(otBu)-Glu-(otBu)-AEEA-AEEA]-OH (CAS NO.: 1662688-20-1). Semaglutide Side Chain serves as a pivotal component in the synthesis of semaglutide, an innovative medication utilized in the treatment of type 2 ...
We are delighted to welcome Roczen to the community of healthcare organisations leveraging Vantage Software! We look forward to working together and helping them deliver exceptional care and support to those living with chronic conditions. Book a Free Demo ...
Finerenone is marketed as KerendiaTM or, in some countries, as FirialtaTM, and approved for the treatment of chronic kidney disease associated with type 2 diabetes (T2D) in more than 70 countries worldwide. In contrast to T2D, which is primarily a chronic metabolic disease, in type 1 diabetes the insulin ...
ByBayer AG
Alertgy has nearly completed the process of miniaturizing its first generation NICGM® (Non-Invasive Continuous Glucose Monitor) into a smaller form factor that will be the size of modern smart watches. By replacing commercial off-the-shelf components with custom built parts, Alertgy has been able to greatly reduce the size of its NICGM. Throughout the design process, Alertgy has aimed to ...
ByAlertgy
About Chronic Kidney Disease in Type 2 Diabetes Chronic kidney disease (CKD) is a common and potentially deadly condition that is widely underrecognized. ...
ByBayer AG
Inversago aims to provide new treatment options that improve the lives of patients affected by metabolic conditions such as diabetic kidney disease (DKD), including diabetic nephropathy (DN), type 1 and type 2 diabetes (T1D / T2D), non-alcoholic steatohepatitis (NASH), complications of obesity ...
“Patients with chronic kidney disease and type 2 diabetes are three times more likely to die from a cardiovascular event than those with type 2 diabetes alone. ...
ByBayer AG
(“Inversago”), a clinical stage biotech company with a unique portfolio of peripherally-acting CB1 inverse agonists, today announced that the first patient has been dosed with INV-202 in a Phase 2 clinical trial in subjects with diabetic kidney disease (DKD). The Phase 2 trial of INV-202, a first-in-class, peripherally-acting CB1 inverse agonist, is a multi-centered, ...
An estimated 415 million people are living with diabetes in the world. Diabetes is a chronic disease, that causes blood sugar levels in your body to become too high, either due to your body not being able to respond properly to insulin or due to your body not being unable to produce any at all. If left untreated, this can lead to serious complications such as heart attack, stroke, obesity, eye ...
The research findings were released today in support of World Diabetes Day, an official United Nations Day, reaching a global audience of over 1 billion people in more than 160 countries1 An estimated 537 million people around the globe have diabetes. ...
ByLifeScan
“Their cumulative experience with public and private biotech companies will be of great value to us as we advance our vision of serving patients suffering from Diabetic Kidney Diseases and Fibrosis with our new class of CB1 inverse agonists”, added Dr. ...
The diabetes vaccine Diamyd is uniquely well positioned to be studied for the prevention of clinical type 1 diabetes considering its strong safety profile and clinical efficacy in recent-onset type 1 diabetes”. ...
” The publication is entitled "Intralymphatic GAD-alum (Diamyd®) improves glycaemic control in Type 1 diabetes with HLA DR3-DQ2", and is expected to become freely accessible shortly in an Open Access version. ...
Inversago aims to provide new treatment options that improve the lives of patients affected by metabolic conditions such as Diabetic Kidney Disease (DKD), including Diabetic Nephropathy (DN), Type 1 and Type 2 Diabetes (T1D / T2D), Non-Alcoholic Steatohepatitis (NASH), complications of obesity ...
The last patient in the investigator-initiated clinical trial DIAGNODE-B has received its additional injection (“booster”) of the therapeutic diabetes vaccine Diamyd®. The trial includes 6 patients with Type 1 diabetes who earlier participated in the DIAGNODE-1 or DIAGNODE-2 trials and who carry ...